Central nervous system involvement in malignant melanoma.
One hundred consecutive patients with cerebral metastases from malignant melanoma were studied in relation to survival from the time of diagnosis of central nervous system (CNS) involvement, response to treatment, characteristics of their primary lesion, and the course of the disease from initial diagnosis to the development of intracranial tumor. After treatment, clinical and investigational evidence of objective regression of cerebral lesions was demonstrable in ten patients who survived with a median of 11.5 months from diagnosis of CNS involvement. In 11 additional patients, CNS disease remained clinically stable for a median period of 7 months. Median survival for the entire group of 100 patients was 2.5 months. However, eight patients (8%) survived longer than 1 year from the time of diagnosis of cerebral metastases, four of whom (4%) survived longer than 2 years; the longest survivor being disease-free and incomplete neurologic remission at more than 82 months. Patients with malignant melanoma metastatic to the brain should be informed of the therapeutic options available for their disease.
Retsas
S
S
Medical Oncology Unit, Westminster Hospital, London, UK.
Gershuny
A R
AR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D008130:Lomustine / Q000008:administration & dosage; D008131:London; D008545:Melanoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D008936:Mitolactol / Q000008:administration & dosage; D011379:Prognosis; D011867:Radioisotope Teletherapy
D008130:Lomustine; D003907:Dexamethasone; D008936:Mitolactol; D006918:Hydroxyurea